What is a 'Target Population'?

Today many assets have the potential to treat a range of different patient populations and needs. Which is why in Nmblr we have allowed for the possibility of a strategic indication sequence. For each additional indication you can create a new target population, invite the team, and decide which aspects of the strategy for the second or third indication etc. you might want to work on.

From a commercial perspective, having the different indication strategies easily accessible in one place is beneficial because it enables streamlined decision-making, enhanced cross-functional alignment, and efficient resource allocation. By centralising strategies for multiple indications, teams can identify synergies, avoid duplication of effort, and rapidly evaluate commercial opportunities and risks across indications. This visibility supports prioritisation, facilitates consistent positioning and messaging, and allows for dynamic adjustment of plans as new data or competitive insights emerge. Ultimately, it helps maximise the asset’s full market potential and accelerates time-to-market for each indication by ensuring all stakeholders are working from the same, up-to-date strategic playbook.

Success stories of indication expansion strategies creating enormous brand value can be found across nearly all therapy areas. From inflammation (e.g., Humira) and oncology (e.g., Keytruda), to neurology (e.g., Lyrica) and ophthalmology (e.g., Eylea), the catalogue of drugs with an ever-expanding list of on-label indications is vast.